A promising antibody building block may have the affinity you want while carrying potential developability liabilities that limit its use in a multispecific format. Addressing those liabilities without compromising the properties that made the molecule valuable requires optimization across multiple parameters.
Join Alloy scientist Dalton Markrush to explore a rapid, multi-parameter approach that integrates in vitro and in silico workflows to evaluate and optimize developability alongside affinity.
In this webinar, attendees will learn how Alloy:
- Evaluates developability alongside affinity in multispecific building blocks
- Integrates in vitro and in silico workflows for rapid, multi-parameter optimization
- Improves limiting properties while monitoring favorable starting characteristics
- Applies these approaches in practice through representative case studies
Featuring Insights from
Dalton Markrush
MS
Dalton Markrush, Associate Director of Protein Analytics at Alloy Therapeutics, develops methods and workflows to accelerate early- and late-stage antibody developability for partner programs. Prior to joining Alloy, Dalton worked on protein analytics and binding at Compass Therapeutics. He holds a master’s degree in biotechnology from Northeastern University.
Sponsored by
.avif)
.avif)
